The National Agency for Drug Safety has alerted Wednesday, October 31, difficulties in supply for some treatments against hemophilia. The director of the French Association of Hemophiliacs assured Saturday that it was not a crisis situation.

Some drugs derived from the blood are difficult to supply, but "there is no crisis," assured AFP Saturday Fabrice Pilorgé, director of the French Association of Hemophiliacs, some of which are concerned by this problem.

This statement comes after a statement issued Wednesday by the National Agency for Safety of Medicines and Health Products (ANSM) on its website, informing of difficulties in supply of seven blood-derived drugs produced by the public biotechnology group LFB.

Following a general power cut at the production site of LFB Biomedicaments in Lille, the production line was interrupted, making batches of plasma-derived medicinal products unusable, according to information published on Saturday by France Info.

"This has been anticipated"

However, even if "situations of tension and rupture exist on some of our drugs, for each situation, a solution is found jointly with the ANSM" , guaranteed a spokesperson of the LFB group, interviewed by AFP.

Dozens of people are affected by the situation, she said.

In addition, the biotechnology group "holds only 10% of the market share in drugs for hemophilia type A affected by this situation," said the director of communication of LFB.

"We are not in a crisis situation where all of a sudden people will find themselves without any solution," confirmed AFP the director of the French Association of Hemophiliacs.

"It's pretty well managed and it's been anticipated," said Pilorgé, noting that this was not new.

"No urgency to act during the weekend"

"There is a lot of pressure for patients to go to their usual treatment center" but "there is no urgency to act during the weekend ," he continued.

A map showing the location of the Hemorrhagic Disease Treatment Centers (CT-MHC), where patients can be treated, is available on a dedicated site (https://mhemo.fr/).

"There is no danger in the house, it is necessary to organize specifically to avoid problems, it is something that hospitals and patients can do from the moment they are informed," did he declare.

At the end of December 2017, approximately 15,000 people with rare hemorrhagic disease and more than 7,000 people with hemophilia were identified in France by the FranceCoag network coordinated by the Public Assistance-Hospitals of Marseille.